Interferon-Gamma profile of mice (Mus musculus L.) after complete SARS-CoV-2 vaccination
Keywords:
COVID-19, virus-like particles, adjuvant, IFN-γ, IgGAbstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have afflicted millions of people in a worldwide pandemic. Several vaccines have been developed to prevent infection and illness. The success of preventing and controlling the COVID-19 by using an effective and efficient vaccine. This study aimed to find out the profile of interferon-gamma (IFN-γ) after COVID-19 vaccination. This study conducted at Animal Laboratory Professor Nidom Foundation (ABSL-3) from December 2021 to February 2022. The present study is an experimental study with a post test only control group design using 90 mice (Mus musculus L.). The test group consisted of mice injected subcutan with 0.1 mL PBS (P1), 0.1 mL adjuvant 1 (P2), 0.1 mL adjuvant 2 (P3), 0.1 mL VLPs SARS-CoV-2 10 μg (P4), 0.1 mL VLPs SARS-CoV-2 dose 50 μg (P5), 0.1 mL VLPs SARS-CoV-2 10 μg + adjuvant 1 (P6), 0.1 mL VLPs SARS-CoV-2 10 μg + adjuvant 2 (P7), 0.1 mL VLPs SARS-CoV-2 50 μg + adjuvant 1 (P8), and 0.1 mL VLPs SARS-CoV-2 50 μg + adjuvant 2 (P9). The data analysed by using ANOVA.
Downloads
References
Ansori, A. N. M., Kusala, M. K. J., Normalina, I., Indrasari, S., Alamudi, M. Y., Nidom, R. V., Santoso, K. P., Rachmawati, K., & Nidom, C. A. (2020) Immunoinformatic Investigation of Three Structural Protein Genes in Indonesian SARS-CoV-2 Isolates. Systematic Reviews in Pharmacy, 11(7), 422-434. http://dx.doi.org/10.31838/srp.2020.7.62
Ansori, A. N. M., Nidom, R. V., Kusala, M. K. J., Indrasari, S., Normalina, I., Nidom, A. N., Afifah, B., Sari, K. B., Ramadhaniyah, N. L., Alamudi, M. Y., Cahyaningsih, U., Santoso, K. P., Kuswanto, H., & Nidom, C. A. (2021) Viroinformatics investigation of B-cell epitope conserved region in SARS-CoV-2 lineage B.1.1.7 isolates originated from Indonesia to develop vaccine candidate against COVID-19. Journal of Pharmacy and Pharmacognosy Research, 9(6), 766–779.
Ashmawy, R., Hamdy, N. A., Elhadi, Y., Alqutub, S. T., Esmail, O. F., Abdou, M., Reyad, O. A., El-Ganainy, S. O., Gad, B. K., Nour El-Deen, A. E., Kamal, A., ElSaieh, H., Elrewiny, E., Shaaban, R., & Ghazy, R. M. (2022). A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines. Journal of Primary Care & Community Health, 13, 21501319221089255. https://doi.org/10.1177/21501319221089255
Axelsson B. (2022). Detection of Cytokine-Secreting Cells by Enzyme-Linked Immunospot (ELISpot). Methods in Molecular Biology, 2386, 61–79. https://doi.org/10.1007/978-1-0716-1771-7_5
Banerjee, A., Lew, J., Kroeker, A., Baid, K., Aftanas, P., Nirmalarajah, K., Maguire, F., Kozak, R., McDonald, R., Lang, A., Gerdts, V., Straus, S. E., Gilbert, L., Li, A. X., Mozafarihashjin, M., Walmsley, S., Gingras, A. C., Wrana, J. L., Mazzulli, T., Colwill, K., Falzarano, D. (2022). Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Med, 3(6), 422–432.e3. https://doi.org/10.1016/j.medj.2022.04.002
Cimica, V., & Galarza, J. M. (2017). Adjuvant formulations for virus-like particle (VLP) based vaccines. Clinical Immunology, 183, 99–108. https://doi.org/10.1016/j.clim.2017.08.004
Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. The Lancet. Infectious Diseases, 20(5), 533–534. https://doi.org/10.1016/S1473-3099(20)30120-1
Gao, N., Qiao, H. L., Jia, L. J., Tian, X., & Zhang, Y. W. (2008). Relationships between specific serum IgE, IgG, IFN-gamma level and IFN-gamma, IFNR1 polymorphisms in patients with penicillin allergy. European Journal of Clinical Pharmacology, 64(10), 971–977. https://doi.org/10.1007/s00228-008-0486-6
Hernández-Bernal, F., Ricardo-Cobas, M. C., Martín-Bauta, Y., Navarro-Rodríguez, Z., Piñera-Martínez, M., Quintana-Guerra, J., Urrutia-Pérez, K., Urrutia-Pérez, K., Chávez-Chong, C. O., Azor-Hernández, J. L., Rodríguez-Reinoso, J. L., Lobaina-Lambert, L., Colina-Ávila, E., Bizet-Almeida, J., Rodríguez-Nuviola, J., Del Valle-Piñera, S., Ramírez-Domínguez, M., Tablada-Ferreiro, E., Alonso-Valdés, M., Lemos-Pérez, G., Muzio-González, V. L. (2022). Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study). EClinicalMedicine, 46, 101383. https://doi.org/10.1016/j.eclinm.2022.101383
Kalyuzhny A. E. (2005). Chemistry and biology of the ELISPOT assay. Methods in Molecular Biology, 302, 15–31. https://doi.org/10.1385/1-59259-903-6:015
Kordzadeh-Kermani, E., Khalili, H., & Karimzadeh, I. (2020). Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). Future Microbiology, 15, 1287–1305. https://doi.org/10.2217/fmb-2020-0110
Lee, A. J., & Ashkar, A. A. (2018). The Dual Nature of Type I and Type II Interferons. Frontiers in Immunology, 9, 2061. https://doi.org/10.3389/fimmu.2018.02061
Lin, H., Zhang, J., Dong, S., Liu, Y., Liu, P., Gao, G. F., Liu, W. J., & Wu, G. (2022). An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses. Biosafety and Health, 4(3), 179–185. https://doi.org/10.1016/j.bsheal.2022.04.005
Moss P. (2022). The T cell immune response against SARS-CoV-2. Nature Immunology, 23(2), 186–193. https://doi.org/10.1038/s41590-021-01122-w
Nidom, R. V., Ansori, A. N. M., Indrasari, S., Normalina, I., Kusala, M. K. J., Saefuddin, A., & Nidom, C. A. (2020a) Recent updates on COVID-19 vaccine platforms and its immunological aspects: a review. Systematic Reviews in Pharmacy, 11(10), 807–818. http://dx.doi.org/10.31838/srp.2020.10.121
Nidom, R. V., Indrasari, S., Normalina, I., Kusala, M. K. J., Ansori, A. N. M., & Nidom, C. A. (2020b) Investigation of the D614G mutation and antibody-dependent enhancement sequences in Indonesian SARS-CoV-2 isolates and comparison to Southeast Asian isolates. Systematic Reviews in Pharmacy, 11(8), 203–213. https://doi.org/10.31838/srp.2020.8.30
Nidom, R. V., Indrasari, S., Normalina, I., Nidom, A. N., Afifah, B., Dewi, L., Putra, A. K., Ansori, A., Kusala, M., Alamudi, M. Y., & Nidom, C. A. (2021). Phylogenetic and full-length genome mutation analysis of SARS-CoV-2 in Indonesia prior to COVID-19 vaccination program in 2021. Bulletin of the National Research Centre, 45(1), 200. https://doi.org/10.1186/s42269-021-00657-0
Nur, M., Nidom, C. A., Indrasari, S., Ansori, A. N. M., Alamudi, M. Y., Nidom, A. N., Sumariyah, Sasmita, E., Yulianto, E., Kinandana, A. W., Usman, A., Kusala, M. K. J., Normalina, I., & Nidom, R. V. (2022) A successful elimination of Indonesian SARS-CoV-2 variants and airborne transmission prevention by cold plasma in fighting COVID-19 pandemic: A preliminary study. Karbala International Journal of Modern Science, 8(3).
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. International Journal of Health Sciences, 5(2), vi-ix. https://doi.org/10.53730/ijhs.v5n2.2937
Tan, A. S., Nerurkar, S. N., Tan, W., Goh, D., Lai, C., & Poh Sheng Yeong, J. (2020). The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research. SLAS Technology, 25(6), 522–544. https://doi.org/10.1177/2472630320950248
Tian, J. H., Patel, N., Haupt, R., Zhou, H., Weston, S., Hammond, H., Logue, J., Portnoff, A. D., Norton, J., Guebre-Xabier, M., Zhou, B., Jacobson, K., Maciejewski, S., Khatoon, R., Wisniewska, M., Moffitt, W., Kluepfel-Stahl, S., Ekechukwu, B., Papin, J., Boddapati, S., & Smith, G. (2021). SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nature Communications, 12(1), 372. https://doi.org/10.1038/s41467-020-20653-8
Khidoyatova, M. R., Kayumov, U. K., Inoyatova, F. K., Fozilov, K. G., Khamidullaeva, G. A., & Eshpulatov, A. S. (2022). Clinical status of patients with coronary artery disease post COVID-19. International Journal of Health & Medical Sciences, 5(1), 137-144. https://doi.org/10.21744/ijhms.v5n1.1858
Vajo Z. (2022). Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection. Viruses, 14(2), 196. https://doi.org/10.3390/v14020196
Xu, K., Dai, L., & Gao, G. F. (2021). Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. International Immunology, 33(10), 529–540. https://doi.org/10.1093/intimm/dxab061
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
